The CenterVue EIDON FA is a confocal scanning ophthalmoscope indicated for color, infrared and autofluorescence imaging and fluorescein angiography of a human retina with or without the use of a mydriatic agent.

Device Description

The CenterVue EIDON FA has been derived from the CenterVue EIDON, a retinal imaging device cleared under K142047. EIDON FA is a scanning ophthalmoscope which uses LED light to capture confocal images of the retina. In particular, EIDON FA uses infrared light to obtain infraredreflectance images, white light to obtain color images and blue light to obtain auto-fluorescence and fluorescence images. EIDON FA can be used with or without pharmacological dilation.

The CenterVue EIDON FA is part of a family of devices, which includes three models: EIDON FA, EIDON AF, and EIDON. EIDON is the base model, which features the following imaging modalities: infrared reflectance, color and red-free. EIDON AF adds autofluorescence imaging to the base model. The EIDON FA is the fully featured device, which adds fluorescein angiography to the capabilities of the EIDON AF and encompasses the features and functionality of the other models.

EIDON FA operates as a standalone unit, running a dedicated software application, is intended for prescription use only, and includes:

an optical head, including a removable lens cap;
a patient head-rest, including a removable front-rest;
a patient chin rest;
a base, including a touch-screen device (tablet with magnetic holder and USB cable), USB joystick and an external power supply.

EIDON FA operates based on the following principles:
a) An illumination system consisting of an infrared (IR) LED (825-875 nm and 940 nm), a white LED (440-650 nm), a blue LED (440-475 nm) and a green LED, illuminates the patient eye with the following functions:

the IR LED with central wavelength at 850 nm allows the capture of IR photos. The patient's retina is uniformly illuminated by a line in a horizontal direction. Along the optical path there is an oscillating mirror which scans the line in order to illuminate the retina with a field of view of 60°.
Two IR LEDs with central wavelength at 940 nm are seen from the eye in a free viewing system. The two LEDs are equally shifted with respect to the machine's optical axis. The LEDS are switched on during all exams in order to enable pupil tracking.
The white and blue LEDs allow the capture of color photos. The retina is uniformly illuminated by a line in the horizontal direction. Along the optical path an oscillating mirror scans the line in order to illuminate the retina with a field of view of 60°.
The blue LED is also used to capture auto-fluorescence and fluorescence retinal images;
The green LED is used as fixation target.
b) An imaging system including a barrier filter (high-pass with a cutoff at 500 nm) stops back reflected light from the retina and allows fluorescent light to be detected for imaging. A focusing lens is included in the imaging path to achieve optimal focusing on a CMOS camera.
c) An anterior segment alignment system is included, using two cameras and the two IR LEDs. The LEDs illuminate the anterior segment by diffusion, whereas allow a stereoscopic reconstruction of the pupil's position to be obtained with respect to the instrument's front lens.

EIDON FA interacts with the patient by directing infrared, white, blue (for imaging) and green (for fixation) illumination into the patient's eye. The chin-rest and head-rest are the only parts of the device that contact the patient. The chin-rest includes a patient proximity sensor and is motorized for height adjustment.

AI/ML Overview

The provided text describes the regulatory information and technical specifications of the CenterVue EIDON FA device, focusing on its substantial equivalence to predicate devices for FDA clearance. However, it does not contain specific acceptance criteria, comprehensive study details, or performance data in the structured format requested. The clinical performance data section is very brief and high-level.

Therefore, I cannot fully complete the requested table and answer all points accurately based solely on the provided text. I will extract and present the available information, and explicitly state where information is missing.

Acceptance Criteria and Device Performance Study for CenterVue EIDON FA

The provided documentation describes the CenterVue EIDON FA as a confocal scanning ophthalmoscope indicated for color, infrared, autofluorescence imaging, and fluorescein angiography of the human retina. The substantial equivalence determination relies on comparisons to predicate devices (CenterVue EIDON, Kowa VX-20, and Heidelberg Spectralis HRA²).

1. Table of Acceptance Criteria and Reported Device Performance

Based on the provided text, the acceptance criteria are not explicitly stated as numerical thresholds or specific performance metrics. Instead, the focus is on demonstrating "substantial equivalence" to predicate devices, particularly regarding imaging capability and safety. The performance is reported qualitatively.

Criterion Type	Acceptance Criteria (Not explicitly stated in quantitative terms)	Reported Device Performance (Summary from text)
Imaging Quality	Implied: Images produced by EIDON FA in all modalities (color, infrared, autofluorescence, fluorescein angiography) must be "similar" to or demonstrate "effectiveness" comparable to the respective predicate devices for their specific imaging functions. The document states "no additional concerns for safety and effectiveness" in comparison to predicates.	"The comparison showed that EIDON FA provides in all modalities images that are similar to those of the mentioned devices." This is a qualitative assessment.
Safety	Implied: The device must meet electrical safety, EMC, light hazard, and general safety standards (e.g., IEC 60601-1, IEC 60601-1-2, ISO 15004-1, ISO 15004-2). Any technological differences with predicates (e.g., higher power LEDs for AF/FA) must not introduce new safety concerns.	"The device complies with the IEC 60601-1:2005 and IEC 60601-1-2:2007 standards." "The device complies with the ISO 15004-1:2006 standard for ophthalmic instruments and with the ISO 15004-2:2007 standard for light hazard protection." "No additional concerns for safety and effectiveness."
Software	Implied: Software must be verified and validated according to FDA guidance and industry standards, with a focus on safety given its "moderate" level of concern.	"Software verification and validation testing were conducted and documentation was provided as recommended by FDA's Guidance for Industry and FDA Staff... The software for this device was considered as a 'moderate' level of concern... The software also complies with the IEC 62304 standard."
Fundus Camera Std.	Implied: The device must comply with relevant fundus camera standards.	"The device complies with the ISO 10940:2009 standard for fundus cameras."

2. Sample Size Used for the Test Set and Data Provenance

Sample Size: The document states, "Images of eyes with and without diagnosed pathology were included in the comparison." However, it does not specify the number of images or patients used in the clinical comparison.
Data Provenance: Not explicitly stated (e.g., country of origin). The study implicitly appears to be retrospective, as it involves comparing EIDON FA images with existing images from predicate devices.

3. Number of Experts Used to Establish Ground Truth and Qualifications

Number of Experts: This information is not provided in the document.
Qualifications of Experts: This information is not provided in the document. The assessment is described as a "comparison" of images, but who performed this comparison (e.g., a panel of ophthalmologists/radiologists or internal staff) and their qualifications are not detailed.

4. Adjudication Method for the Test Set

The document does not describe any specific adjudication method (e.g., 2+1, 3+1) for the clinical image comparison. The assessment seems to be a general comparison.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

No, a MRMC study comparing human readers with and without AI assistance was not mentioned or performed. This submission is for an imaging device, not an AI-powered diagnostic algorithm designed to assist human readers. The clinical performance data section describes a comparison of image quality between the EIDON FA device and predicate devices.

6. Standalone (Algorithm Only) Performance

This question is not applicable as the EIDON FA is an imaging device, not an AI algorithm. Its "performance" refers to the quality of the images it produces, which are then interpreted by a human clinician.

7. Type of Ground Truth Used

The "ground truth" for the clinical comparison was implicitly the diagnosed pathology of the eyes. The study included "images of eyes with and without diagnosed pathology." The comparison was about the similarity of images captured by EIDON FA to those from predicate devices, rather than a direct diagnostic accuracy assessment against a gold standard for a specific condition.

8. Sample Size for the Training Set

This question is not applicable, as the device is an imaging system and not an AI algorithm that requires a training set in the typical machine learning sense. The "training" of the device is its manufacturing and calibration process, not data-driven machine learning.

9. How the Ground Truth for the Training Set Was Established

This question is not applicable for the same reason as point 8.

Summary

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.

July 16, 2018

CenterVue SpA Roberto Gabriotti Quality and Regulatory Affairs Manager Via S. Marco 9H Padova, 35129 ITALY

Re: K180526

Trade/Device Name: EIDON FA Regulation Number: 21 CFR 886.1570 Regulation Name: Ophthalmoscope Regulatory Class: Class II Product Code: MYC Dated: June 5, 2018 Received: June 7, 2018

Dear Roberto Gabriotti:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{1}------------------------------------------------

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely.

Alexander Beylin -S 2018.07.16 16:50:49 -04'00' for Malvina B. Evdelman, M.D. Director Division of Ophthalmic and Ear. Nose and Throat Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Indications for Use

510(k) Number (if known)

K180526

Device Name

EIDON FA

Indications for Use (Describe)

Type of Use (Select one or both, as applicable)

▽ Prescription Use (Part 21 CFR 801 Subpart D)

| | Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

Image /page/3/Picture/1 description: The image shows a logo with a stylized globe design. The globe is composed of gray and yellow squares, creating a three-dimensional effect. At the center of the globe is a black circle, resembling an eye or a focal point.

centervue

Regulatory information

Device Name:	EIDON FA
Type of 510(k) submission:	Traditional
Date summary prepared:	July 3rd, 2018
Manufacturer:	CenterVue S.p.A.via San Marco 9h35129 Padova Italy
510(k) Submitter and Contact:	Mr. Roberto GabriottiCentervue S.p.A.Manager of Quality and Regulatory AffairsVia San Marco 9H35129 Padova ItalyPhone: +39 049 501 8399Fax: +39 049 501 8398E-mail: roberto.gabriotti@centervue.com
Product Code:	MYC
Regulation Number:	886.1570
Classification Name:	Ophthalmoscope, Laser, Scanning
Panel:	Ophthalmic
FDA Classification:	Class II
Indications for use:	The CenterVue EIDON FA is a confocal scanningophthalmoscope indicated for color, infrared and auto-fluorescence imaging and fluorescein angiography of ahuman retina with or without the use of a mydriatic agent.

{4}------------------------------------------------

Image /page/4/Picture/1 description: The image shows the logo for Centervue. The logo features a stylized globe made of gray and yellow squares, with a black circle in the center, resembling an eye. Below the globe is the word "centervue" in a sans-serif font, with "center" in black and "vue" in yellow.

Device description

EIDON FA operates as a standalone unit, running a dedicated software application, is intended for prescription use only, and includes:

1. an optical head, including a removable lens cap;
1. a patient head-rest, including a removable front-rest;
1. a patient chin rest;
ধ: a base, including a touch-screen device (tablet with magnetic holder and USB cable), USB joystick and an external power supply.

EIDON FA operates based on the following principles:

An illumination system consisting of an infrared (IR) LED (825-875 nm and 940 nm), a a) white LED (440-650 nm), a blue LED (440-475 nm) and a green LED, illuminates the patient eye with the following functions:
- the IR LED with central wavelength at 850 nm allows the capture of IR photos. The patient's retina is uniformly illuminated by a line in a horizontal direction. Along the optical path there is an oscillating mirror which scans the line in order to illuminate the retina with a field of view of 60°.
- · Two IR LEDs with central wavelength at 940 nm are seen from the eye in a free viewing system. The two LEDs are equally shifted with respect to the machine's optical axis. The LEDS are switched on during all exams in order to enable pupil tracking.
- The white and blue LEDs allow the capture of color photos. The retina is uniformly illuminated by a line in the horizontal direction. Along the optical path an oscillating mirror scans the line in order to illuminate the retina with a field of view of 60°.
- · The blue LED is also used to capture auto-fluorescence and fluorescence retinal images;
- · The green LED is used as fixation target.
An imaging system including a barrier filter (high-pass with a cutoff at 500 nm) stops backb) reflected light from the retina and allows fluorescent light to be detected for imaging. A focusing lens is included in the imaging path to achieve optimal focusing on a CMOS camera.
An anterior segment alignment system is included, using two cameras and the two IR c) LEDs. The LEDs illuminate the anterior segment by diffusion, whereas allow a stereoscopic reconstruction of the pupil's position to be obtained with respect to the instrument's front lens.

{5}------------------------------------------------

Image /page/5/Picture/1 description: The image contains the logo for Centervue. The logo features a stylized eye made up of yellow and gray blocks, with a black pupil in the center. Below the eye is the word "centervue" in a lowercase sans-serif font, with the "vue" portion of the word in yellow.

Technical Specifications

Class and type of applied part

Class I, Type B (according to IEC 60601-1).

IP classification:

IPX0 (according to the degree of protection provided by the enclosure with respect to harmful penetration of particulate matter or water).

Image acquisition:

Minimum pupil size: 2.5 mm Field of individual image: 60° (H) x 55° (V) captured in a single exposure ● Sensor resolution: 14 MP (4608x3288 pixels) . ● Light sources: infrared LED (825-870 nm), white LED (440-650 nm), blue LED (440-475nm) ● lmaqing modalities: color, red-free, IR reflectance, autofluorescence (AF), fluorescein angiography (FA) ● Working distance: 28 mm Resolution: 60 pixels / deg. ● ● Resolution on retina: 15 microns ● Pixel pitch: 4.9 µm FA video resolution: 1840x1622 pixels ●
FA video acquisition rate: 5 fps ●

DICOM:

· Compatibility: DICOM version 3.0

Other features:

· Automatic operation: auto-alignment, auto-focus, auto-exposure, auto-capture
Focus adjustment range: . -12D to +15D
Internal fixation target: dynamic, programmable
· Display: 10.1" multi-touch, color tablet
· Hard disk: SSD, 2 TB

Dimensions:

· Weight: 25Kg (55lb) • Size (W x H x D): 360mm x 590mm x 620mm (14.2" x 23.2" x 24.4")

{6}------------------------------------------------

K180526

Image /page/6/Picture/1 description: The image shows the logo for Centervue. The logo features a stylized eye made up of gray and yellow squares, with a black pupil in the center. Below the eye is the word "centervue" in a sans-serif font, with the "vue" portion in a lighter color.

Power supply:

Voltage: 12 V DC; Power consumption: 60 W .

Predicate devices

The predicate devices selected for comparison with EIDON FA are identified as follows:

Predicate Device 1 (primary):

Device Name:	EIDON
Manufacturer:	CenterVue S.p.A.
510(k) Number:	K142047
Product Code:	MYC
Classification Name:	Ophthalmoscope, Laser, Scanning
Regulation No:	886.1570

Predicate Device 2:

Device Name:	KOWA VX-20
Manufacturer:	Kowa Company, Ltd.
510(k) Number:	K112330
Product Code:	HKI, NFJ
Classification Name:	Camera, Ophthalmic, AC-powered
Regulation No:	886.1120

Predicate Device 3:

Device Name:	Spectralis HRA²
Manufacturer:	Heidelberg Engineering Gmbh
510(k) Number:	K172649
Product Code:	MYC
Classification Name:	Ophthalmoscope, Laser, Scanning
Regulation No:	886.1570

Comparison of technological characteristics with the predicate device(s)

The following technological differences exist between the subject device and the primary predicate device:

Difference	Equivalence discussion
Capability for autofluorescence imaging,driving the blue LED at higher power andusing an insertable barrier filter	No additional concerns for safety and effectivenessas the subject device is equivalent to the primarypredicate in terms of safety and to the SpectralisHRA in terms of effectiveness
Capability for fluorescein angiographydriving the blue LED at higher power,	No additional concerns for safety and effectivenessas the subject device is equivalent to the KOWA VX-

1 Neither the EIDON nor the EIDON FA contain lasers but rather use LEDs for confocal imaging

² The Spectralis is considered only in relation to its imaging functions, while the OCT function is not relevant

{7}------------------------------------------------

firing the flash at higher frequency andusing an insertable barrier filter	20 in terms of safety and equivalent to the SpectralisHRA in terms of effectiveness
--------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------

Performance data - bench

The following performance data were provided in support of the substantial equivalence determination.

Electrical safety and electromagnetic compatibility (EMC) The device complies with the IEC 60601-1:2005 and IEC 60601-1-2:2007 standards.

Software Verification and Validation Testing

Software verification and validation testing were conducted and documentation was provided as recommended by FDA's Guidance for Industry and FDA Staff, "Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices." The software for this device was considered as a "moderate" level of concern, since a failure or latent flaw in the software could directly result in minor injury. The software also complies with the IEC 62304 standard for software life cycle processes.

Fundus cameras testing

The device complies with the ISO 10940:2009 standard for fundus cameras.

Light hazard testing

The device complies with the ISO 15004-1:2006 standard for ophthalmic instruments and with the ISO 15004-2:2007 standard for light hazard protection.

Performance data - clinical

The imaging properties of the EIDON FA were assessed by comparing color and infrared images taken with EIDON FA with the same images taken using the primary predicate device (CenterVue EIDON, K142047) and by comparing auto-fluorescein angiography images taken with EIDON FA with the same images taken using predicate device 3 (Heidelberg SPECTRALIS, K172649). Images of eyes with and without diagnosed pathology were included in the comparison. The comparison showed that EIDON FA provides in all modalities images that are similar to those of the mentioned devices.

Conclusions

Based on the information contained within this submission, it is concluded that the CenterVue EIDON FA is substantially equivalent to the identified predicate devices already in interstate commerce within the USA, and that any differences that do exist have no effect on the safety and effectiveness of the device.

Regulation Number and Section

§ 886.1570 Ophthalmoscope.

(a)
Identification. An ophthalmoscope is an AC-powered or battery-powered device containing illumination and viewing optics intended to examine the media (cornea, aqueous, lens, and vitreous) and the retina of the eye.(b)
Classification. Class II (special controls). The device, when it is an AC-powered opthalmoscope, a battery-powered opthalmoscope, or a hand-held ophthalmoscope replacement battery, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 886.9.